Naxcel Inj.

The Exact match is NOT found. Probably you are looking for: Naxcel Inj.

advertisement

Here is the some steps to help you to save money on Naxcel Inj. purchase.

Read drug prescription

  1. CAUTION
  2. DESCRIPTION
  3. INDICATIONS
  4. CONTRAINDICATIONS
  5. WARNINGS
  6. RESIDUE WARNINGS
  7. PRECAUTIONS
  8. ADVERSE REACTIONS
  9. CLINICAL PHARMACOLOGY
  10. EFFECTIVENESS
  11. ANIMAL SAFETY
  12. STORAGE CONDITIONS
  13. HOW SUPPLIED


infoIt is very important to know about what medicine is given by the doctor, for what condition, and when it needs to be taken in what dose. This information given by the doctor is called Prescription. The patients should be familiar with the medicine prescription, and the details about the medicine before purchasing it and using it. Some medications need not be prescribed by healthcare practitioners and can be purchased and used without prescription by the patients; these are called over-the-counter medications. Read the drug prescription information of Naxcel Inj. before taking it.

Naxcel Inj. uses

Naxcel Inj. FOR
SWINE

For intramuscular administration in the post-auricular region of the neck of swine.

CAUTION

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Federal Law prohibits extra-label use of this drug in swine for disease prevention purposes; at unapproved doses; frequencies, durations, or routes of administration; and in unapproved major food producing species/production classes.

DESCRIPTION

EXCEDE FOR SWINE Sterile Suspension 100 mg/mL is a ready-to-use formulation that contains the crystalline free acid of Naxcel Inj., which is a broad spectrum cephalosporin antibiotic active against gram-positive and gram-negative bacteria including ß-lactamase-producing strains. Like other cephalosporins, Naxcel Inj. is bactericidal in vitro, resulting from inhibition of cell wall synthesis.
Each mL of this ready-to-use sterile suspension contains Naxcel Inj. crystalline free acid equivalent to 100 mg Naxcel Inj., in a Miglyol® and cottonseed oil based suspension.
Figure 1. Structure of Naxcel Inj. crystalline free acid:
Chemical name of Naxcel Inj. crystalline free acid:
7-[[2-(2-Amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-3-[[(2-furanylcarbonyl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene 2-carboxylic acid
Chemical Structure
advertisement

INDICATIONS

EXCEDE FOR SWINE Sterile Suspension 100 mg/mL is indicated for the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Streptococcus suis; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Streptococcus suis in groups of pigs where SRD has been diagnosed.
DOSAGE
Administer by intramuscular (IM) injection in the post-auricular region of the neck as a single dosage of 2.27 mg Naxcel Inj. equivalents (CE)/lb (5.0 mg CE/kg) body weight (BW). This is equivalent to 1 mL sterile suspension per 44 lb (20 kg) BW. No more than 2 mL should be injected in a single injection site. Injection volumes in excess of 2 mL per injection site may result in violative residues. Pigs heavier than 88 lb (40 kg) will require more than one injection.
Most animals will respond to treatment within three to five days. If no improvement is observed, the diagnosis should be re-evaluated.
ADMINISTRATION
Shake well before using. EXCEDE FOR SWINE Sterile Suspension 100 mg/mL is to be administered by intramuscular injection in the post-auricular region of the neck.
advertisement

CONTRAINDICATIONS

As with all drugs, the use of EXCEDE FOR SWINE Sterile Suspension 100 mg/mL is contraindicated in animals previously found to be hypersensitive to the drug.

WARNINGS

FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN.
Penicillins and cephalosporins can cause allergic reactions in sensitized individuals. Topical exposures to such antimicrobials, including Naxcel Inj., may elicit mild to severe allergic reactions in some individuals. Repeated or prolonged exposure may lead to sensitization. Avoid direct contact of the product with the skin, eyes, mouth and clothing. Sensitization of the skin may be avoided by wearing protective gloves.
Persons with a known hypersensitivity to penicillin or cephalosporins should avoid exposure to this product.
In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. If allergic reaction occurs (e.g., skin rash, hives, difficult breathing), seek medical attention.
The material safety data sheet contains more detailed occupational safety information. To report adverse effects in users, to obtain more information or to obtain a material safety data sheet, call 1-888-963-8471.
advertisement

RESIDUE WARNINGS

  • A maximum of 2 mL of formulation should be injected at each injection site. Injection volumes in excess of 2 mL per injection site may result in violative residues.
  • Following label use as a single treatment, a 14-day pre-slaughter withdrawal period is required.
  • Use of dosages in excess of 5.0 mg Naxcel Inj. equivalents (CE)/kg or administration by an unapproved route may result in illegal residues in edible tissues.

PRECAUTIONS

The safety of Naxcel Inj. has not been demonstrated for pregnant swine or swine intended for breeding.
Administration of EXCEDE FOR SWINE Sterile Suspension 100 mg/mL as directed may induce a transient reaction at the site of injection and underlying tissues that may result in trim loss of edible tissue at slaughter.

ADVERSE REACTIONS

An injection site tolerance study demonstrated that EXCEDE FOR SWINE Sterile Suspension 100 mg/mL is well tolerated in pigs. Half of the injection sites at both 3 and 7 days post-injection were scored as "negative" for irritation and the other half were scored as "slight irritation". All gross observations and measurements of injection sites qualified the sites at 10 days post-injection as "negative" for irritation.
No adverse effects were observed in multi-location field efficacy studies involving more than 1000 pigs.
advertisement

CLINICAL PHARMACOLOGY

Naxcel Inj. administered as either Naxcel Inj. sodium, Naxcel Inj. hydrochloride (EXCENEL® RTU Sterile Suspension) or Naxcel Inj. crystalline free acid (EXCEDE FOR SWINE Sterile Suspension 100 mg/mL) is metabolized rapidly to desfuroylceftiofur, the primary metabolite. Administration of Naxcel Inj. to swine as Naxcel Inj. crystalline free acid (CCFA) at a single IM dosage of 2.27 mg CE/lb (5.0 mg CE/kg) BW provides concentrations of Naxcel Inj. and desfuroylceftiofurrelated metabolites in plasma that are multiples above the MIC90 Minimum inhibitory concentration for 90% of the isolates for the SRD label pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis and Streptococcus suis for an extended period of time .
The average plasma concentrations of ceftiofur- and desfuroylceftiofur-related metabolites for CCFA (EXCEDE FOR SWINE Sterile Suspension 100 mg/mL) after IM administration of 2.27 mg CE/lb (5.0 mg CE/kg) BW and those for Naxcel Inj. sodium (NAXCEL Sterile Powder) after IM administration at 1.36 mg CE/lb (3 mg CE/kg) BW for three consecutive days are presented in Figure 2 below.
Figure 2. Average plasma concentrations of ceftiofur- and desfuroylceftiofur-related metabolites for CCFA (EXCEDE FOR SWINE Sterile Suspension 100 mg/mL) after IM administration of 2.27 mg CE/lb (5.0 mg CE/kg) BW and those for Naxcel Inj. sodium (NAXCEL Sterile Powder) after IM administration at 1.36 mg CE/lb (3 mg CE/kg) BW for three consecutive days

Pharmacokinetic parameters measured after a single IM administration of 2.27 mg CE/lb (5.0 mg CE/kg) BW of EXCEDE FOR SWINE Sterile Suspension 100 mg/mL in the post-auricular region of the neck of swine are presented in the following table (Table 1).
Pharmacokinetic
Parameter
Mean Value ± Standard Deviation
(non-compartmental analyses)
Cmax = maximum plasma concentration (in μg CE/mL)
tmax = the time after injection when Cmax occurs (in hours)
AUC 0-LOQ = the area under the plasma concentration vs. time curve from time of injection to the limit of quantitation of the assay (0.15 μg CE/mL)
t1/2 = terminal phase biological half-life (in hours)
Cmax (μg/mL) 4.17 ± 0.92
tmax (h) 22.0 ± 12.2
AUC 0-LOQ (μg∙h/mL) 373.0 ± 56.1
t1/2 (h) 49.6 ± 11.8
Indicated Pathogens Year(s) of Isolation Field Study Number of Isolates MIC50 The lowest MIC to encompass 50% and 90% of the most susceptible isolates, respectively.
(μg/mL)
MIC90
(μg/mL)
MIC Range
(μg/mL)
Actinobacillus pleuropneumoniae 2000 to 2001 Treatment 5 NA NA ≤0.03 to 0.06
2009 Control 34 0.03 0.06 0.015 to 0.06
Pasteurella multocida 2000 to 2001 Treatment 20 ≤0.03 ≤0.03 ≤0.03No range; all isolates yielded the same value.
2009 Control 67 ≤0.004 ≤0.004 ≤0.004
Streptococcus suis 2000 to 2001 Treatment 30 0.06 0.12 ≤ 0.03 to 0.5
2009 Control 141 0.25 1 0.03 to >2
Figure 2

MICROBIOLOGY

Naxcel Inj. has demonstrated in vitro activity against Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Streptococcus suis, four major pathogenic bacteria associated with SRD.
The minimum inhibitory concentrations (MICs) of Naxcel Inj. against indicated SRD pathogens were determined using methods recommended by the Clinical and Laboratory Standards Institute (CLSI) using the M31-A and M31-A3 standards for the SRD treatment (2000-2001) and control (2009) studies, respectively. Isolates from the SRD treatment study were obtained from lung tissue collected from non-treated pigs prior to enrollment and saline-treated pigs that died or were euthanized during the study. Isolates from the SRD control study were obtained from lung tissue from non-treated pigs euthanized prior to enrollment and from saline- and ceftiofur-treated pigs that died or were euthanized during the study. The susceptibility results for the treatment and control studies are presented in Table 2.
Based on pharmacokinetic data from studies of Naxcel Inj. in swine after a single intramuscular injection of 2.27 mg CE/lb (5.0 mg CE/kg) BW, the following interpretive criteria are recommended by CLSI:
Pathogens Disk Potency Zone Diameter
(mm)
MIC
(μg/mL)
Interpretation
Actinobacillus pleuropneumoniae
Pasteurella multocida
Streptococcus suis
30 μg ≥21 ≤2.0 (S) Susceptible
18-20 4.0 (I) Intermediate
≤17 ≥8.0 (R) Resistant
advertisement

EFFECTIVENESS

The effectiveness of a single dose of 2.27 or 3.18 mg CE/lb BW (5.0 or 7.0 mg CE/kg BW) EXCEDE FOR SWINE Sterile Suspension 100 mg/mL for the treatment of SRD was confirmed in a well-controlled, multi-location field study. A total of 706 pigs with clinical signs of bacterial respiratory disease were enrolled and treated with a placebo injection or EXCEDE FOR SWINE Sterile Suspension 100 mg/mL administered as a single IM injection in the post-auricular region of the neck. Clinical observations were performed on Days 1-7 and rectal temperatures were taken on Days 1, 3, and 6 following treatment (Day 0). Necropsies were performed on all pigs that died during the study and after euthanasia of all remaining study pigs at the end of the 14-day post-enrollment study period. Lung lesions were scored and lungs were submitted for bacterial identification. Mortality rates were numerically lower (but not statistically different) for the EXCEDE FOR SWINE Sterile Suspension 100 mg/mL-treated groups (4.3% for the 5.0 mg CE/kg BW group and 4.2% for the 7.0 mg CE/kg BW group) compared with the placebo-treated control group (6.3%). There was a statistically significant (p<0.05) improvement in clinical cure rates for the EXCEDE FOR SWINE Sterile Suspension 100 mg/mL-treated groups (24.8% for the 5.0 mg CE/kg BW group and 26.4% for the 7.0 mg CE/kg BW group) compared with the placebo-treated control group (17.7%). Lung lesion scores were numerically higher (but not statistically different) for the EXCEDE FOR SWINE Sterile Suspension 100 mg/mL-treated groups (10.4% for both the 5.0 mg CE/kg BW and the 7.0 mg CE/kg BW group) compared with the placebo-treated control group (9.2%). Bacteriological culture of the lungs of study pigs identified the following respiratory pathogens: Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Streptococcus suis.
The effectiveness of a single dose of 2.27 CE/lb BW (5.0 mg CE/kg BW) EXCEDE FOR SWINE for the control of SRD was evaluated in a multi-location natural infection field study. At each site, when at least 15% of the study candidates in a pen showed clinical signs of SRD, all pigs in the pen were enrolled and treated with EXCEDE FOR SWINE (n = 346) or saline (n = 347). Responses to treatment were evaluated 7 days post-treatment. Success was defined as a pig that survived to Day 7 and had normal attitude, normal respiration, and a rectal temperature of < 104 °F. The treatment success rate was significantly higher (p = 0.0188) for EXCEDE FOR SWINE-treated pigs (59.6%) compared to the saline-treated pigs (41.4%). Bacteriological culture of the lungs of study pigs identified the following respiratory pathogens: Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Streptococcus suis.
advertisement

ANIMAL SAFETY

After parenteral administration, CCFA, Naxcel Inj. sodium, and Naxcel Inj. hydrochloride are metabolized to the same principal metabolite, desfuroylceftiofur. Plasma levels achieved are similar after recommended dosing (Figure 2). Therefore, studies conducted with Naxcel Inj. sodium are adequate to evaluate the systemic safety of CCFA. Results from a five-day tolerance study in normal feeder pigs indicated that Naxcel Inj. sodium produced no overt adverse signs of toxicity and was well tolerated when administered at 57 mg CE/lb (125 mg/kg) BW (more than 25 times the recommended dosage of CCFA) for five consecutive days.
Organism Name (ATCC No.) MIC (μg/mL) Zone Diameter, mm
(Disk Content 30 μg)
E. coli ATCC 25922 0.25–1.0 26–31
S. aureus ATCC 29213 0.25–1.0 -
S. aureus ATCC 25923 - 27–31
P. aeruginosa ATCC 27853 16.0–64.0 14–18

An additional dose toxicity study was conducted to determine the safety margin of Naxcel Inj. in swine. Five barrows and five gilts per group were administered Naxcel Inj. sodium IM at 0, 2.27, 6.81 and 11.36 mg CE/lb (0, 5, 15, 25 mg CE/kg) BW (0, 1, 3 and 5 times the recommended dosage for CCFA) for 15 consecutive days. There were no adverse systemic effects observed, indicating that Naxcel Inj. sodium has a wide margin of safety when administered intramuscularly in feeder pigs.
A separate study evaluated the injection site tissue tolerance of EXCEDE FOR SWINE Sterile Suspension 100 mg/mL in swine when administered intramuscularly as a single injection at the maximum recommended dose volume of 2 mL (approximately 5 mg CE/kg BW) per injection site. Because injection site volumes greater than 2 mL may result in violative residues, only injection volumes of 2 mL were evaluated in this study. EXCEDE FOR SWINE Sterile Suspension 100 mg/mL was injected intramuscularly into each side of the neck of six swine at a dose volume of 2 mL/injection site. Clinical observations were made daily. At 3, 7 and 10 days post-injection, pairs of animals were euthanized and the neck injection sites were dissected for pathological examination (4 injection sites per time point). The injections were well tolerated in all pigs. Clinically, injection site reactions ranged from nondetectable (6 of 12 sites) to a transitory (up to 4 days post-injection) palpable, nonvisible swelling (2 of 12 sites) or a small, visible, reddened nodule at the needle insertion point (4 of 12 sites; 3 of 4 nodules were barely detectable by 3 to 7 days post-injection). There was no clinical evidence of the injections at 10 days post-injection. At necropsy, half of the injection sites at both 3 and 7 days post-injection were scored as "negative" for irritation and the other half were scored as "slight irritation". One animal had a visible lesion described as an area of tan with red speckles present in the deep muscle fascia, less than 6 cm2, at 10 days post-injection; this lesion and the remaining injection sites evaluated at 10 days post-injection were scored as "negative" for irritation.
advertisement

STORAGE CONDITIONS

Store at controlled room temperature 20° to 25°C (68° to 77°F). Shake well before using. Contents should be used within 12 weeks after the first dose is removed.

HOW SUPPLIED

EXCEDE FOR SWINE Sterile Suspension 100 mg/mL is available in the following package size:
100 mL vial
NADA # 141-235, Approved by FDA
Distributed by:
Zoetis Inc.
Kalamazoo, MI 49007
www.excede.com or call
1-888-963-8471
Revised: November 2013
11148001

Compare prices at online shops

infoPrices of the drug can vary in different shops. There will be a variation in price from pharmacy to an online shop. Most online shops will have a little lower price when compared to pharmacy stores, so you need to cross check before buying. Just go to a nearest pharmacy store and check for prices before you decide on buying. You should also be checking and comparing prices among various online stores and should be choosing the affordable and best store. The prices also vary based on brands, and you should note few stores sell specific brands, and you should learn to compare prices of same brand in different stores. Below are the prices of Naxcel Inj. medicine in some well-known online stores.

StrengthQuantityPrice, USDCountry
mg1 $58.00Australia, Canada, India, Mauritius, NZ, Singapore, Turkey, UK, USA
mg1 $60.00Australia, Canada, India, Mauritius, NZ, Singapore, Turkey, UK
mg1 $52.00Australia, Canada, India, Mauritius, NZ, Singapore, Turkey, UK, USA


Select the most affordable brand or generic drug

infoGeneric drug is the basic drug with an active substance in it, and the name of the generic drug is same as active substance most of the times. Like Acetaminophen/Paracetemol is Generic name and it has different brand names like Tylenol, Acimol, Crocin, Calpol etc. All these Brand names contain the same Paracetemol, but the medications are manufactured by different companies, so the different brand names. Generic drug is always cheaper and affordable, and it can be replaced in place of brand name drug prescribed by the healthcare practitioner. The Generic medicine has same properties as branded medicine in terms of uses, indications, doses, side effects, so no need to worry on that. Just select the most affordable generic or branded medicine.

StrengthQuantityPrice, USDCountry

Naxcel Inj. - Frequently asked Questions

Can Naxcel Inj. be stopped immediately or do I have to stop the consumption gradually to ween off?

In some cases, it always advisable to stop the intake of some medicines gradually because of the rebound effect of the medicine.

It's wise to get in touch with your doctor as a professional advice is needed in this case regarding your health, medications and further recommendation to give you a stable health condition.

Can Naxcel Inj. be taken or consumed while pregnant?

Please visit your doctor for a recommendation as such case requires special attention.

Can Naxcel Inj. be taken for nursing mothers or during breastfeeding?

Kindly explain your state and condition to your doctor and seek medical advice from an expert.

advertisement

Reviews

Following the study conducted by wDrugs.com on Naxcel Inj., the result is highlighted below. However, it must be clearly stated that the survey and result is based solely on the perception and impression of visitors and users of the website as well as consumers of Naxcel Inj.. We, therefore, urge readers not to base their medical judgment strictly on the result of this study but on test/diagnosis duly conducted by a certified medical practitioners or physician.

Patient reports

Patient reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 25 here

The information was verified by Dr. Harshad Shah, MD Pharmacology